EPIX - ESSAファ―マ （ESSA Pharma Inc.） ESSAファ―マEPIXのチャート
EPIXの企業情報
| symbol | EPIx |
|---|---|
| 会社名 | ESSA Pharma Inc （ESSAファ―マ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | ― 医療関連（Health Care） |
| 概要 | 事業概要 -- ESSAファ―マはカナダのバイオ医薬品企業。主に臨床開発ステ―ジで、去勢抵抗性前立腺がんの治療に向けた小分子薬の開発を行う。同社はアンドロゲン受容体のアミノ末端領域を選択的にブロックする薬を開発し、既知のアンドロゲン受容体に依存する抵抗メカニズムを克服して前立腺がんの治療に当たる。本社はバンク―バ―。 ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. |
| 本社所在地 | 900 West Broadway Suite 720 Vancouver British Columbia V5Z 1K5 CAN |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | 39814 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 25人 |
| url | www.essapharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/epix |
| adr_tso | ― |
| EBITDA | EBITDA ー |
| 終値（lastsale） | 3.25 |
| 時価総額（marketcap） | 18772318.5 |
| 時価総額 | 時価総額 ― |
| 売上高 | 売上高 -- |
| 企業価値(EV) | 企業価値(EV) ー |
| 当期純利益 | 当期純利益 -- |
| 決算概要 | 決算概要 -- |
EPIXのテクニカル分析
EPIXのニュース
ESSA Pharma Inc. (EPIX) deserves closer scrutiny 2022/11/24 13:32:00 US Post News
ESSA Pharma Inc. (NASDAQ:EPIX) marked $3.11 per share on Wednesday, down from a previous closing price of $3.19. While ESSA Pharma Inc. has underperformed by -2.51%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, EPIX fell by -76.24%, with highs and lows ranging from $14.88 to […]
How did ESSA Pharma Inc. (EPIX) fare last session? 2022/11/16 12:48:00 US Post News
As of Tuesday, ESSA Pharma Inc.’s (NASDAQ:EPIX) stock closed at $3.98, up from $3.38 the previous day. While ESSA Pharma Inc. has overperformed by 17.75%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, EPIX fell by -69.36%, with highs and lows ranging from $14.88 to $1.40, […]
ESSA Pharma: Combination Shows Efficacy In Prostate Cancer (TSXV:EPI:CA) 2022/11/16 03:01:32 Seeking Alpha
ESSA has been in the investor spotlight after the recently presented data for its product candidate EPI-7386 with Xtandi. Read why EPIX stock is a Buy.
Fantasy Injury Updates: Latest news on Cordarrelle Patterson, James Conner, D''Andre Swift more RBs impacting Week 9 start ''em, sit ''em calls 2022/11/06 16:33:00 Kwhen Finance
ESSA Pharma Shares Tank As Janssen Stops Enrollment In EPI-7386 Combo Prostate Cancer Trials 2022/10/31 15:13:22 Benzinga
ESSA Pharma Inc (NASDAQ: EPIX ) announced that Johnson & Johnson''s (NYSE: JNJ ) Janssen is suspending enrollment into the Phase 1 study of EPI-7386 with apalutamide or EPI-7386 with abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer (mCRPC) patients due to operational challenges. Before suspending enrollment, Janssen treated three mCRPC patients (pre-chemotherapy) with the combination of … Full story available on Benzinga.com
Things To Consider Before Buying ESSA Pharma Inc. (NASDAQ: EPIX) 2022/08/06 19:00:00 Stocks Register
ESSA Pharma Inc. (NASDAQ:EPIX) shares, rose in value on Friday, 08/05/22, with the stock price down by -0.66% to the previous day’s close as strong demand from buyers drove the stock to $3.00. Actively observing the price movement in the last trading, the stock closed the session at $3.02, falling within a range of $2.95 … Things To Consider Before Buying ESSA Pharma Inc. (NASDAQ: EPIX) Read More »
ESSA Pharma GAAP EPS of -$0.20 2022/08/04 12:47:00 Seeking Alpha
ESSA Pharma press release (EPIX): FQ3 GAAP EPS of -$0.20 (vs
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2022 2022/08/04 11:00:00 PR Newswire
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Aug. 4, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate…
Essa Pharma trades 6% higher after 10% owner buys more shares 2022/07/21 16:05:48 Seeking Alpha
Essa Pharma (EPIX) is trading 6% higher after its 10% owner Growth Biotech bought 300,000 common shares at $3.1558 for $947K.Growth Biotech now owns 5,879,583 common shares.
EPIX Stock Gains 11.6% on Insider Buys 2022/07/21 14:50:05 TipRanks
Shares of ESSA Pharma (NASDAQ: EPIX) have tanked 22% in the past month, while the short interest in the stock stood at 4.5%. However, shares have been on an upswing in the past five days, going up by 11.6% following corporate insiders'' buying of the stock. EPIX is a clinical-stage pharmaceutical company that develops novel therapies for the treatment of prostate cancer. The pharma company has seen an uptick in insider interest with BB Biotech AG, holding a more than 10% stake in EPIX, loading up on its shares. BB Biotech bought shares worth $945,000 on July 20 and $1.7 million on July 18, respectively.
Things To Consider Before Buying ESSA Pharma Inc. (NASDAQ: EPIX) 2022/08/06 19:00:00 Stocks Register
ESSA Pharma Inc. (NASDAQ:EPIX) shares, rose in value on Friday, 08/05/22, with the stock price down by -0.66% to the previous day’s close as strong demand from buyers drove the stock to $3.00. Actively observing the price movement in the last trading, the stock closed the session at $3.02, falling within a range of $2.95 … Things To Consider Before Buying ESSA Pharma Inc. (NASDAQ: EPIX) Read More »
ESSA Pharma GAAP EPS of -$0.20 2022/08/04 12:47:00 Seeking Alpha
ESSA Pharma press release (EPIX): FQ3 GAAP EPS of -$0.20 (vs
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2022 2022/08/04 11:00:00 PR Newswire
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Aug. 4, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate…
Essa Pharma trades 6% higher after 10% owner buys more shares 2022/07/21 16:05:48 Seeking Alpha
Essa Pharma (EPIX) is trading 6% higher after its 10% owner Growth Biotech bought 300,000 common shares at $3.1558 for $947K.Growth Biotech now owns 5,879,583 common shares.
EPIX Stock Gains 11.6% on Insider Buys 2022/07/21 14:50:05 TipRanks
Shares of ESSA Pharma (NASDAQ: EPIX) have tanked 22% in the past month, while the short interest in the stock stood at 4.5%. However, shares have been on an upswing in the past five days, going up by 11.6% following corporate insiders'' buying of the stock. EPIX is a clinical-stage pharmaceutical company that develops novel therapies for the treatment of prostate cancer. The pharma company has seen an uptick in insider interest with BB Biotech AG, holding a more than 10% stake in EPIX, loading up on its shares. BB Biotech bought shares worth $945,000 on July 20 and $1.7 million on July 18, respectively.